The News: Oracle Cloud’s Volunteer Screening Registry is a key part of the NIH’s COVID-19 Prevention Network (CoVPN). The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), has partnered with Oracle Cloud as part of the agencies’ COVID-19 Prevention Network (CoVPN) to develop a COVID-19 Volunteer Screening Registry. The goal of the initiative is to register millions of volunteers for large scale testing of vaccines and antibodies in the battle against COVID-19. Oracle’s cloud-based system, called the CoVPN Volunteer Screening Registry, was designed to identify and screen volunteers who want to participate in clinical trials. Read the full release from Oracle.
Analyst Take: Oracle’s announcement on Oracle Cloud being used to build the CoVPN Volunteer Screening Registry for the NIH is yet another move by Big Tech in pandemic times that can make a significant contribution to society as a whole — at least here in the U.S.
This Volunteer Screening Registry is part of efforts of the NIH to support healthcare providers, medical researchers, and the Department of Health and Human Services (HHS). One of the benefits that our team here at Futurum often looks for when analyzing cloud provider services is the ability to scale. The NIH’s CoVPN network will put Oracle’s cloud capabilities to the test, as it aims to register millions of volunteers as part of this effort. In fact, once the CVPN Volunteer Screening Registry went live and in less than a week’s time more than 100,000 people had already registered as volunteers for the clinical trials.
Another cloud benefit that we often write about is the accelerated go-to-market of products. The NIH expects the CoVPN to support hundreds of clinical trial sites in the U.S. and internationally by year’s end. This puts a lot of pressure on Oracle to support millions of volunteer screening registrants for an abundant amount of clinical trials very quickly. The trials are open to everyone from all communities, with a focus on those who are at higher risk for COVID-19. This Volunteer Screening Registry initiative is designed to help health professionals collect and analyze the data necessary to better understand and combat COVID-19.
Similar to the other major could providers, this is not the first of Oracle’s COVID-19 projects. In April, the vendor developed a Therapeutic Learning System (TLS) that allows physicians and patients to record responses to COVID-19 drug therapies. Oracle has done this in partnership with health systems such as Wake Forest Baptist Health and Javara Research. Patients log their symptoms on smartphones giving healthcare professionals immediate access to early warning signs of negative side effects. This initiative has now been extended to include patient monitoring and over 1.5 million patient updates have already been recorded in the TLS system. If you’d like more information on how Oracle is helping industries navigate COVID-19, you’ll find that here.
As Oracle has spent the past five years placing heavy emphasis on its cloud offerings, the company should be well-equipped to handle the scale and fast-tracked pace of the CoVPN registry. A global pandemic is a time for today’s high-performance computing and cloud capabilities to shine, and we’re betting that Oracle is a vendor that can handle a demanding task such as this that will help the medical community and the general public on a global scale.
The NIH encourages those interested in learning more to visit the CoVPN website. If you’re interested in volunteering for a COVID-19 Prevention Clinical Study, you can do that here.
As Oracle has spent the past five years placing heavy emphasis on its cloud offerings, the company should be well-equipped to handle the scale and fast-tracked pace of the CoVPN registry. A global pandemic is a time for today’s high-performance computing and cloud capabilities to shine, and we’re betting that Oracle is a vendor that can handle a demanding task such as this that will help the medical community and the general public on a global scale.
The NIH encourages those interested in learning more to visit the CoVPN website. If you’re interested in volunteering for a COVID-19 Prevention Clinical Study, you can do that here.
Futurum Research provides industry research and analysis. These columns are for educational purposes only and should not be considered in any way investment advice.
Oracle Delivers Solid Q4 Despite Ongoing Covid-19 Woes
Oracle Announces Updates to its Fusion Supply Chain Cloud
Oracle Announces Its Fully Managed Region Cloud@Customer
The original version of this article was first published on Futurum Research.
In this guest contribution from Steve Vonder Haar, Senior Analyst with Wainhouse, a Futurum Group…
In this guest contribution from Craig Durr, Senior Analyst with Wainhouse, a Futurum Group Company,…
Futurum's Daniel Newman dives into the recent announcement coming out of Micron, that they will…
Futurum analyst Michael Diamond recaps the Amazon Devices and Services event and reviews some of…
Futurum senior analyst Steven Dickens provides his take on the latest announcements coming out of…
Futurum’s Ron Westfall and Daniel Newman examine Micron’s financial results for the fourth quarter 2022…